Literature DB >> 16331251

Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells.

F De Oliveira1, C Chauvin, X Ronot, M Mousseau, X Leverve, E Fontaine.   

Abstract

As mitochondria play a key role in the commitment to cell death, we have investigated the mitochondrial consequences of resistance to doxorubicin (DOX) in K562 cells. We found that the permeability transition pore (PTP) inhibitor cyclosporine A (CsA) failed to inhibit PTP opening in the resistant clone. Moreover, the Ca2+ loading capacity in the resistant clone was identical to that observed in the parent cells in the presence of CsA, suggesting that the PTP was already inhibited in a CsA-like manner in the resistant cells. In agreement with this proposal, the mitochondrial target of CsA cyclophilin D (CyD) decreased by half in the resistant cells. The levels of adenine nucleotide translocator, voltage anion-dependent channel, Bax, Bcl-2, Bcl-xL, AIF and Smac/Diablo, were similar in both cell lines, whereas cytochrome c content was divided by three in the resistant cells. Since P-glycoprotein inhibition did not restore DOX toxicity in the resistant cells, while DOX-induced cell death in the parent cells was prevented by either PTP inhibition or siRNA-induced decrease in cytochrome c content, we conclude that the inhibition of PTP opening and the decrease in cytochrome c content participate in the mechanism that makes K562 cells resistant to DOX.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331251     DOI: 10.1038/sj.onc.1209293

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  A tocotrienol-enriched formulation protects against radiation-induced changes in cardiac mitochondria without modifying late cardiac function or structure.

Authors:  Vijayalakshmi Sridharan; Preeti Tripathi; Nukhet Aykin-Burns; Kimberly J Krager; Sunil K Sharma; Eduardo G Moros; Stepan B Melnyk; Oleksandra Pavliv; Martin Hauer-Jensen; Marjan Boerma
Journal:  Radiat Res       Date:  2015-02-24       Impact factor: 2.841

2.  Ubiquinone analogs: a mitochondrial permeability transition pore-dependent pathway to selective cell death.

Authors:  Flavien Devun; Ludivine Walter; Julie Belliere; Cécile Cottet-Rousselle; Xavier Leverve; Eric Fontaine
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

3.  Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.

Authors:  Yanlong Ji; Shasha Wei; Junjie Hou; Chengqian Zhang; Peng Xue; Jifeng Wang; Xiulan Chen; Xiaojing Guo; Fuquan Yang
Journal:  Oncotarget       Date:  2017-02-21

4.  3D Quantitative and Ultrastructural Analysis of Mitochondria in a Model of Doxorubicin Sensitive and Resistant Human Colon Carcinoma Cells.

Authors:  Claudia Moscheni; Emil Malucelli; Sara Castiglioni; Alessandra Procopio; Clara De Palma; Andrea Sorrentino; Patrizia Sartori; Laura Locatelli; Eva Pereiro; Jeanette A Maier; Stefano Iotti
Journal:  Cancers (Basel)       Date:  2019-08-27       Impact factor: 6.639

Review 5.  Reactive Oxygen Species Interact With NLRP3 Inflammasomes and Are Involved in the Inflammation of Sepsis: From Mechanism to Treatment of Progression.

Authors:  Shuai Zhao; Fan Chen; Qiliang Yin; Dunwei Wang; Wei Han; Yuan Zhang
Journal:  Front Physiol       Date:  2020-11-25       Impact factor: 4.566

6.  Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer.

Authors:  Xiulan Chen; Shasha Wei; Ying Ma; Jie Lu; Gang Niu; Yanhong Xue; Xiaoyuan Chen; Fuquan Yang
Journal:  Theranostics       Date:  2014-09-18       Impact factor: 11.556

7.  Miltirone exhibits antileukemic activity by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction pathways.

Authors:  Ling Zhou; Lifeng Jiang; Maolei Xu; Qun Liu; Ning Gao; Ping Li; E-Hu Liu
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.